FIBROGEN WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG Forum: Aktien Thema: Hauptdiskussion

FibroGen GAAP EPS of -$0.98 misses by $0.16, revenue of $15.7M misses by $15.89M https://seekingalpha.com/news/3903012-fibrogen-gaap-eps-of-0_98-misses-0_16-revenue-of-15_7m-misses-15_89m • FibroGen press release (NASDAQ:FGEN): Q3 GAAP EPS of -$0.98 misses by $0.16. • Revenue of $15.7M (-89.9% Y/Y) misses by $15.89M. • At September 30, 2022, FibroGen had $441.6 million in cash - defined as cash, cash equivalents, investments, and accounts receivable.

FibroGen Reports Third Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/11/07/2550183/33525/en/FibroGen-Reports-Third-Quarter-2022-Financial-Results.html • Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024 • Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodysplastic syndromes with topline data expected 1H 2023 • Strong roxadustat volume growth in China of over 80% vs 3Q 2021

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management https://www.globenewswire.com/news-release/2022/11/07/2550172/33525/en/FibroGen-Announces-50-Million-Royalty-Monetization-Financing-with-NovaQuest-Capital-Management.html • Strengthens balance sheet with strategic non-dilutive capital to support strategic priorities • Supported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc. • FibroGen will receive $50 million in total cash upfront

FibroGen GAAP EPS of -$0.78 beats by $0.19, revenue of $29.81M misses by $6.34M https://seekingalpha.com/news/3869168-fibrogen-gaap-eps-of-0_78-beats-0_19-revenue-of-29_81m-misses-6_34m • FibroGen press release (NASDAQ:FGEN): Q2 GAAP EPS of -$0.78 beats by $0.19. • Revenue of $29.81M (+22.4% Y/Y) misses by $6.34M.

FibroGen Reports Second Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/08/08/2494238/33525/en/FibroGen-Reports-Second-Quarter-2022-Financial-Results.html • Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy • 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021 • Continued significant roxadustat volume growth in China ...

https://www.globenewswire.com/news-release/2022/06/08/2458555/33525/en/FibroGen-Announces-Completion-of-Patient-Enrollment-in-LELANTOS-2-a-Phase-3-Clinical-Study-of-Pamrevlumab-in-Duchenne-Muscular-Dystrophy.html FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

📌📌📌

FibroGen GAAP EPS of -$0.68 beats by $0.24, revenue of $60.8M beats by $32.04M https://seekingalpha.com/news/3835294-fibrogen-gaap-eps-of-0_68-beats-0_24-revenue-of-60_8m-beats-32_04m • FibroGen press release (NASDAQ:FGEN): Q1 GAAP EPS of -$0.68 beats by $0.24. • Revenue of $60.8M (+58.2% Y/Y) beats by $32.04M. • Based on our latest forecast, we estimate a 2022 ending cash balance of $310-340 million.

FibroGen Reports First Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/05/09/2439011/33525/en/FibroGen-Reports-First-Quarter-2022-Financial-Results.html • Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis • 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 • Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction

FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results https://www.globenewswire.com/news-release/2022/02/28/2393644/33525/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html • Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer • Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy • Total company revenue increased from $176.3 million in 2020 to $235.3 million in 2021

https://www.globenewswire.com/news-release/2021/12/20/2355186/33525/en/FibroGen-Exercises-Exclusive-License-Option-for-HiFiBiO-s-CCR8-Program.html

FibroGen Reports Third Quarter 2021 Financial Results https://finance.yahoo.com/news/fibrogen-reports-third-quarter-2021-210100110.html • Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a $120M milestone payment from Astellas • Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. • Total roxadustat net sales in China of $57.8 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca

was ist den hier los? nichts? sollte schon einmal steigen.

https://www.globenewswire.com/news-release/2021/08/25/2286187/33525/en/FibroGen-Announces-Positive-Topline-Results-from-Phase-2-Clinical-Trial-of-Roxadustat-for-the-Treatment-of-Chemotherapy-Induced-Anemia.html

FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial https://www.benzinga.com/general/biotech/21/08/22654151/fibrogens-roxadustat-aces-chemo-induced-anemia-trial

bin hier auch investiert und hatte schon meine Zweifel....